CPT1A and metabolic dysfunction-associated steatotic liver disease: Furthermore, different studies have shown that the use of activators of AMPK (via phosphorylation) could be a useful strategy to improve NAFLD, boosting fatty acid oxidation by enhancing CPT1α flux [82].